tiprankstipranks
Advertisement
Advertisement

URGN Stock Latest News

UroGen Pharma reports month results from UTOPIA trial
The FlyUroGen Pharma reports month results from UTOPIA trial
2d ago
URGN
UroGen Pharma presents 36-month ENVISION trial data
PremiumThe Fly
UroGen Pharma presents 36-month ENVISION trial data
4d ago
URGN
UroGen Pharma assumed with a Buy at Ladenburg
PremiumThe Fly
UroGen Pharma assumed with a Buy at Ladenburg
6d ago
URGN
UroGen Pharma price target raised to $45 from $40 at H.C. Wainwright
PremiumThe Fly
UroGen Pharma price target raised to $45 from $40 at H.C. Wainwright
6d ago
URGN
UroGen Pharma Earnings Call Highlights ZUSDURI Surge
PremiumCompany Announcements
UroGen Pharma Earnings Call Highlights ZUSDURI Surge
9d ago
URGN
UroGen Pharma price target raised to $40 from $34 at Oppenheimer
PremiumThe FlyUroGen Pharma price target raised to $40 from $34 at Oppenheimer
10d ago
URGN
UroGen Pharma reports Q1 EPS (47c), consensus (36c)
Premium
The Fly
UroGen Pharma reports Q1 EPS (47c), consensus (36c)
10d ago
URGN
Bancroft Maintains Buy on Zusduri as Commercial Momentum Builds and $35 Price Target Remains Unchanged
Premium
Ratings
Bancroft Maintains Buy on Zusduri as Commercial Momentum Builds and $35 Price Target Remains Unchanged
10d ago
URGN
UroGen Pharma: Undervalued Chemoablative Disruptor in NMIBC With Blockbuster Potential by 2030
PremiumRatings
UroGen Pharma: Undervalued Chemoablative Disruptor in NMIBC With Blockbuster Potential by 2030
24d ago
URGN
UroGen Pharma initiated with a Buy at Jefferies
PremiumThe Fly
UroGen Pharma initiated with a Buy at Jefferies
1M ago
URGN
UroGen Pharma publishes results from ENVISION trial of Zusduri
PremiumThe Fly
UroGen Pharma publishes results from ENVISION trial of Zusduri
2M ago
URGN
UroGen Pharma ‘commends’ BCAN release of Bladder Cancer Report
PremiumThe Fly
UroGen Pharma ‘commends’ BCAN release of Bladder Cancer Report
2M ago
URGN
Building Momentum With Zusduri: Strong Early Commercial Traction, Expanding Physician Adoption, and Pipeline-Funded Upside Support a Buy Rating
PremiumRatingsBuilding Momentum With Zusduri: Strong Early Commercial Traction, Expanding Physician Adoption, and Pipeline-Funded Upside Support a Buy Rating
2M ago
URGN
UroGen Pharma Earnings Call: Launch Momentum Meets Rising Costs
Premium
Company Announcements
UroGen Pharma Earnings Call: Launch Momentum Meets Rising Costs
2M ago
URGN
UroGen Pharma: ZUSDURI Launch Momentum, Strengthening Balance Sheet, and Path to Profitability Support Buy Rating
Premium
Ratings
UroGen Pharma: ZUSDURI Launch Momentum, Strengthening Balance Sheet, and Path to Profitability Support Buy Rating
2M ago
URGN
Trade Tensions Put UroGen Pharma’s Margins, Pipeline and Growth at Risk
PremiumCompany Announcements
Trade Tensions Put UroGen Pharma’s Margins, Pipeline and Growth at Risk
2M ago
URGN
UroGen Pharma Secures New $250 Million Term Loan
PremiumCompany Announcements
UroGen Pharma Secures New $250 Million Term Loan
3M ago
8K
URGN
UroGen Pharma reports Q4 EPS (54c), consensus (51c)
PremiumThe Fly
UroGen Pharma reports Q4 EPS (54c), consensus (51c)
3M ago
URGN
UroGen Pharma sees FY26 net sales for Jelmyto $97M-$101M
PremiumThe Fly
UroGen Pharma sees FY26 net sales for Jelmyto $97M-$101M
3M ago
URGN
UroGen Pharma announces refinanced term loan agreement with Pharmakon
PremiumThe FlyUroGen Pharma announces refinanced term loan agreement with Pharmakon
3M ago
URGN
URGN Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
URGN Upcoming Earnings Report: What to Expect?
3M ago
URGN
UroGen Pharma announces post-hoc analyses from Phase 3 trial of Zusduri
Premium
The Fly
UroGen Pharma announces post-hoc analyses from Phase 3 trial of Zusduri
3M ago
URGN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >